Coalition for Epidemic Preparedness Innovations

CEPI, Coalition for Epidemic Preparedness Innovations, is a "public-private coalition that aims to derail epidemics by speeding up the development of vaccines"[1]

The concept is to develop early phases of vaccines without knowing the details for the form in which the infection will appear, but will still cut down the time to tailor the eventual vaccine to be effective to the epidemic.

CEPI's plan includes preparations for possible outbreaks of Lassa fever, Marburg fever, Middle East Respiratory Syndrome (MERS), SARS, Nipah virus, Rift Valley fever, chikungunya, and others. It is being funded by the Wellcome Trust, the Bill and Melinda Gates Foundation, the World Economic Forum, the governments of Norway, Germany, Japan[2] and India.[3] [4]

As of April 2018, CEPI has invested $37.5 million in Austria-based Themis Bioscience[5] and $56 million in US-based Inovio Pharmaceuticals, Inc.[6] to develop vaccine candidates against Lassa fever and MERS.

References

  1. ↑ John Cohen (2 September 2016). "New vaccine coalition aims to ward off epidemics". Science. 353 (6303).
  2. ↑ https://www.bloomberg.com/news/articles/2017-01-18/ebola-zika-push-drugmakers-to-join-effort-to-avert-pandemics
  3. ↑ "Putting shots in the locker". The Economist. 420 (9003): 67–68. 3 September 2016.
  4. ↑ "Coalition for Epidemic Preparedness Innovations".
  5. ↑ "CEPI Partners with Themis Bioscience to Advance Vaccines Against Lassa Fever and MERS – Press Release". Retrieved 2018-04-15.
  6. ↑ "Inovio Awarded up to $56 Million from CEPI to Advance DNA Vaccines Against Lassa Fever and MERS – Press Release". GlobeNewswire News Room. Retrieved 2018-04-15.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.